Tay Angelique Sao-Mai S, Black Keith L, Yu John S
Department of Neurosurgery, Cedars-Sinai Medical Center, 127 South San Vicente Blvd, AHSP A6600, Los Angeles, California, 90048, USA.
Adv Exp Med Biol. 2023;1394:51-72. doi: 10.1007/978-3-031-14732-6_4.
Major advances have been made in our understanding of CNS tumors, especially glioma, however, the survival of patients with malignant glioma remains poor. While radiation and chemotherapy have increased overall survival, glioblastoma multiforme (GBM) still has one of the worst 5-year survival rates of all human cancers. Here, in this chapter, the authors review the abrogation of the immune system in the tumor setting, revealing many plausible targets for therapy and the current immunotherapy treatment strategies employed. Notably, glioma has also been characterized as a subset of primary spinal cord tumor and current treatment recommendations are outlined here.
我们对中枢神经系统肿瘤，尤其是胶质瘤的认识取得了重大进展，然而，恶性胶质瘤患者的生存率仍然很低。虽然放疗和化疗提高了总体生存率，但多形性胶质母细胞瘤（GBM）仍是所有人类癌症中5年生存率最差的癌症之一。在本章中，作者回顾了肿瘤环境中免疫系统的缺失，揭示了许多可能的治疗靶点以及目前采用的免疫治疗策略。值得注意的是，胶质瘤也被归类为原发性脊髓肿瘤的一个子集，此处概述了当前的治疗建议。
